Publicaciones destacadas

A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

Prat A; Tsai YH; Pascual T; Paré L; Adamo B;

(...)

Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS .

Referencia:
Clinical Cancer Research 2020.
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S;

(...)

Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A .

Referencia:
Clinical Cancer Research 2020.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Schettini F; Pascual T; Conte B; Chic N; Brasó-Maristany F;

(...)

Osborne CK; Pernas S; Perou CM; Carey LA; Prat A.

Referencia:
Cancer Treatment Reviews 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

(...)

Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

Referencia:
Nature Communications 2020.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Prat A; Saura C; Pascual T; Hernando C; Muñoz M;

(...)

López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J .

Referencia:
Lancet Oncology 2020.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A;

(...)

Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.

Referencia:
Journal Of The National Cancer Institute 2020.
Immune-related adverse events of checkpoint inhibitors

Ramos-Casals M; Brahmer JR; Callahan MK; Flores-Chávez A; Keegan N;

Khamashta MA; Lambotte O; Mariette X; Prat A; Suárez-Almazor ME .

Referencia:
Nature Reviews Disease Primers 2020.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S;

(...)

Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R .

Referencia:
Annals Of Oncology 2019.
Patients’ Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS)

Font C; Nelson A; Garcia-Fernandez T; Prout H; Gee P;

Noble S.

Referencia:
Supportive Care In Cancer 2018.
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer

Martín A; Ortega I; Font C; Pachón V; Castellón V;

(...)

Rupérez A; Souto J; Martín M; Salas E; Soria J.

Referencia:
British Journal Of Cancer 2018.